ERBB2 and breast carcinoma: Concurrently, Liu et al. demonstrated that ALKBH5-mediated m6A demethylation of GLUT4 mRNA enhances glycolytic activity in breast cancer cells and contributes to resistance against HER2-targeted therapies107.